Chairman of the Board
Stephen C. McCluski
Stephen C. McCluski has been a director of ImmunoGen since 2007, and has served as the Chairman of our Board of Directors since 2009. Mr. McCluski served as Senior Vice President and Chief Financial Officer of Bausch & Lomb Incorporated from 1995 to his retirement in 2007. Mr. McCluski is also a director of Monro Muffler Brake, Inc. and the James P. Wilmot Cancer Center of the University of Rochester.
Stuart A. Arbuckle
Stuart A. Arbuckle has served as a director of ImmunoGen since 2018. Mr. Arbuckle has more than 30 years of experience in building biopharmaceutical commercial organizations and has served as Vertex’s Executive Vice President and Chief Commercial Officer since 2012, leading the successful global launches of Kalydeco® and Orkambi®. Prior to joining Vertex, Mr. Arbuckle held multiple commercial leadership roles at Amgen, Inc., most recently serving as Vice President and Regional General Manager overseeing the expansion of the company’s presence in Japan, Asia, the Middle East, and Africa. As Vice President and General Manager of Amgen’s Oncology Business Unit, he was responsible for sales and marketing efforts for Aranesp®, Neulasta® and NEUPOGEN®, and led the successful launches of XGEVA® and Nplate®. Prior to Amgen, Mr. Arbuckle held commercial roles of increasing responsibility at Celltech Pharmaceuticals and GlaxoSmithKline. He also previously served as a member of Cerulean Pharma’s Board of Directors. He is currently a national board member of the Cancer Support Community, a member of the Executive Committee and Health Section Governing Board for the Biotechnology Innovation Organization (BIO), and is co-chair of the BIO Standing Committee on Access and Value. Mr. Arbuckle has a degree in pharmacology and physiology from the University of Leeds in the United Kingdom.
President and Chief Executive Officer
Mr. Enyedy joined ImmunoGen in 2016 as President and CEO, bringing over twenty-five years of combined general management, business development and legal experience in the biotechnology industry. He joined ImmunoGen from Shire plc, where he served as Executive Vice President and Head of Corporate Development, leading the company’s Strategy, M&A, and Corporate Planning functions and providing commercial oversight for the company’s pre-Phase 3 portfolio. Previously, Mr. Enyedy served as CEO of Proteostasis Therapeutics, Inc., following 15 years at Genzyme Corporation in diverse roles, most recently as President of the Transplant, Oncology, and Multiple Sclerosis divisions. Before joining Genzyme, Mr. Enyedy was an associate with the Boston law firm Palmer & Dodge. He holds a J.D. from Harvard Law School and a B.S. from Northeastern University. Mr. Enyedy also serves on the Board of Directors of Fate Therapeutics and Keryx Biopharmaceuticals.
Mark Goldberg, MD
Mark Goldberg, MD, has been a director of ImmunoGen since 2011. Dr. Goldberg served in various capacities of increasing responsibility at Synageva BioPharma Corp., a biopharmaceutical company, from 2011 to 2014, including as Executive Vice President, Medical and Regulatory Strategy of Product Development. From October 2014 through the acquisition of Synageva by Alexion Pharmaceuticals, Inc. in June 2015, Dr. Goldberg, while no longer an officer, remained employed by Synageva contributing to medical and regulatory strategy. Prior to joining Synageva he served in various management capacities of increasing responsibility at Genzyme Corporation from 1996 to 2011, most recently as Senior Vice President, Clinical Research and Global Therapeutic Head, Oncology, Genetic Health, and as Chairman of Genzyme’s Early Product Review Board. Prior to joining Genzyme he was a full-time staff physician at Brigham and Women’s Hospital and the Dana-Farber Cancer Institute, where he still holds appointments. Dr. Goldberg is an Associate Professor of Medicine at Harvard Medical School. Dr. Goldberg holds a Doctor of Medicine degree from Harvard Medical School. Dr. Goldberg is also a director of aTyr Pharma, Inc., Blueprint Medicines Corporation, GlycoMimetics, Inc. and Idera Pharmaceuticals, Inc.
Daniel M. Junius
Daniel M. Junius has been a director of ImmunoGen since 2008. Mr. Junius joined ImmunoGen in 2005, and served as our President and Chief Executive Officer from 2009-2016. Mr. Junius holds a Master of Management from Northwestern University’s Kellogg School of Management. Mr. Junius is also a director of IDEXX Laboratories, Inc. and GlycoMimetics, Inc.
Dean J. Mitchell
Dean J. Mitchell has been a director of ImmunoGen since 2012. Mr. Mitchell has served as Executive Chairman of the Board of Covis Pharma Holdings S.a.r.l. since 2013. Prior to that he served as President and Chief Executive Officer of Lux Biosciences, Inc. from 2010 to August 2013. Prior to that he served as President and Chief Executive Officer of Alpharma, Inc. from 2006 until its acquisition by King Pharmaceuticals, Inc. in 2008. Prior to that he served as President and Chief Executive Officer of Guilford Pharmaceuticals, Inc. from 2004 until its acquisition by MGI PHARMA, INC. in 2005. Prior to that he served in various senior executive capacities in the worldwide medicines group of Bristol-Myers Squibb Company from 2001 to 2004. Prior to that he spent 14 years at GlaxoSmithKline plc in assignments of increasing responsibility spanning sales, marketing, general management, commercial strategy and clinical development and product strategy. Mr. Mitchell is also a director of Inrexon, Inc. and Theravance BioPharma, Inc.
Kristine Peterson has served as director of ImmunoGen since 2012. Ms. Peterson served as Chief Executive Officer of Valeritas, Inc. from 2009-2016. Prior to that she served as Company Group Chair of Johnson & Johnson’s biotech groups from 2006 to 2009, and as Executive Vice President for J&J’s global strategic marketing organization from 2004 to 2006. Prior to that she served as Senior Vice President, Commercial Operations for Biovail Corporation and President of Biovail Pharmaceuticals from 2003 to 2004. Prior to that she spent 20 years at Bristol-Myers Squibb Company in assignments of increasing responsibility spanning marketing, sales and general management, including running a cardiovascular/metabolic business unit and a generics division. Ms. Peterson is also a director of Amarin Corporation plc and Paratek Pharmaceuticals, Inc.
Joseph J. Villafranca, PhD
Joseph J. Villafranca, PhD, has served as director of ImmunoGen since 2004. Dr. Villafranca has served as President of BioPharmaceutical Consultants LLC since 2012. Prior to that he served as Senior Vice President, SOU Head, Life Sciences, of Tunnell Consulting from 2009 to his retirement from Tunnell Consulting in 2012. Prior to that he served as Senior Vice President – Operations and Principal & Practice Director, Life Sciences, of Tunnell Consulting from 2006 to 2009. Prior to that he served as President of Biopharmaceutical Consultants LLC from 2005 to 2006. Prior to that he served as Executive Vice President, Pharmaceutical Development and Operations at Neose Technologies, Inc. from 2002 to 2005. Prior to that he served in various executive positions at Bristol-Myers Squibb Company over a period of 11 years. Dr. Villafranca holds a PhD in Biochemistry/Chemistry from Purdue University and completed his postdoctoral work at the Institute for Cancer Research in Philadelphia, Pennsylvania.
Richard J. Wallace
Richard J. Wallace has been a director of ImmunoGen since 2007. Mr. Wallace served as a Senior Vice President for Research and Development at GlaxoSmithKline plc (GSK) from 2004 to his retirement in 2008. Prior to that he served in various executive capacities for GSK and its predecessor companies and their subsidiaries from 1992 to 2004. Mr. Wallace’s experience prior to joining GSK included eight years with Bristol-Myers Squibb Company and seven years at Johnson & Johnson (in assignments spanning marketing, sales, manufacturing and general management). Mr. Wallace is also a director of GNC Holdings, Inc.